Adam Dilluvio

Adam Dilluvio is a partner in Goodwin’s Life Sciences group and Healthcare practice. Adam represents life sciences and healthcare companies throughout all aspects of the business life cycle and has particular expertise in mergers and acquisitions, leveraged buyouts, minority investments, early-stage financings, restructurings, carve-outs, joint ventures and strategic licenses.

Adam leverages his prior in-house experience as General Counsel at Gurnet Point Capital, a private equity fund specializing in life sciences and healthcare buyouts, where he oversaw all legal and compliance functions for the fund. In addition, Adam served on the board of directors of numerous Gurnet Point portfolio companies, providing founders and management with strategic guidance and support on a full range of complex legal and business issues.

Adam’s representative experience includes:

Mergers and Acquisitions

• Gurnet Point in its $462 million take private of Paratek Pharmaceuticals, Inc. alongside Novo Holdings*
• Gurnet Point in its $890 million take private of Radius Health, Inc. alongside Patient Square Capital*
• Gurnet Point in its spin-out of Corium Innovations, Inc. from Corium Therapeutics, LLC and corresponding sale to Webster Equity Partners for $400 million*
• Gurnet Point in its majority investment in Tremeau, Inc., a clinical stage biotechnology company specializing in non-opioid pain treatments*
• BFlexion in its acquisition of Allergy Partners, the largest U.S. group of single-specialty allergy and asthma practices*
• Before Brands, Inc. in its sale of minority equity stake to Nestle Health Science*
• Verizon Communications Inc. in connection with its $4.4 billion acquisition of AOL Inc.*
• Iron Mountain Incorporated in connection with its $2.5 billion acquisition of Recall Holdings Limited*
• Elizabeth Arden Inc. in connection with its sale of Series A Serial Preferred Stock and warrants to Rhône Capital L.L.C.*
• Globalfoundries Inc. in connection with its acquisition of IBM’s global commercial semiconductor business*
• Eli Lilly and Company in connection with its acquisition of Glycostasis, Inc.*
• The Jordan Company LP in connection with its acquisition of Gulfstream Services, Inc.*
• American Securities LLC in connection with its acquisition of Emerald Performance Materials, LLC*
• aPriori Capital Partners L.P. in connection with its sale of Deffenbaugh Disposal, Inc. to Waste Management Holdings, Inc.*

Venture Capital

• Gurnet Point in its Series A and Series A-1 investments in Naveris, Inc., a healthcare diagnostics company focused on the early detection of virus-related cancers*
• Gurnet Point in its Series C and D investments in Alladapt Immunotherapeutics, Inc., a clinical-stage biopharmaceutical company developing prescription therapeutics to address IgEmediated food allergies*
• Gurnet Point in its Series A investment in Auregen Biotherapeutics, Inc., a biotechnology company focused on developing regenerative therapies using bioengineering and cellular technologies to repair or replace damaged tissues*
• Gurnet Point in its Series A investment in Mahana Therapeutics, Inc., a prescription digital therapeutics company*
• Crossover Health in its $168 million Series D financing round*

Licensing & Collaboration and Strategic Alliances

• Corium Pharmaceuticals LLC in its exclusive worldwide license to develop, manufacture and commercialize KemPharm Inc.’s product candidates containing serdexmethylphenidate and d-methylphenidate (now known commercially as Azstarys™)*
• Boston Pharmaceuticals in its exclusive license agreement with Novartis to develop the drug candidate BOS-580, for the treatment of Non-Alcoholic Steatohepatitis (NASH)*
• Boston Pharmaceuticals in an exclusive multiyear out-license and option agreement with GSK for the advancement of multiple pre-phase 2 programs*
• Before Brands, Inc. in its License and Option Agreement with Nestle Health Science for the ex-US rights to SpoonfulOne*

*Denotes experience prior to joining Goodwin

Prior to joining Goodwin, Adam was General Counsel at Gurnet Point Capital and Senior Counsel at B-Flexion. He was previously an investment banking associate at Raymond James & Associates and began his career as an associate at Weil Gotshal & Manges LLP.